Termination of early pregnancy through a combination of the antiprogestin and prostaglandin analogue

Eur J Obstet Gynecol Reprod Biol. 1990 Oct;37(1):35-40. doi: 10.1016/0028-2243(90)90092-f.

Abstract

Termination of early pregnancy (less than 49 days of amenorrhea) was induced in 75 patients with the combination of the antigestagen mifepristone and a prostaglandin analogue, meteneprost. After 48 h a single oral dose of 600 mg of mifepristone was followed by a 10 mg meteneprost vaginal pessary. Pregnancy was confirmed by clinical and ultrasound examinations and plasma HCG assessment. Complete abortion occurred in 72 patients (96%) and the three others required a surgical uterine aspiration. Bleeding continued for 4 to 12 days (mean = 8). Uterine pain and side effects occurred during the 3 h following the use of prostaglandin. Only minor analgesic were required in 30 patients. The combination of mifepristone and meteneprost is a safe and effective method to terminate an early pregnancy.

PIP: Termination of early pregnancy (49 days of amenorrhea) was induced in 75 patients with the combination of the antigestagen mifepristone and a prostaglandin (PG) analogue, meteneprost. After 48 hours, a single oral dose of 600 mg mifepristone was followed by a 10 mg meteneprost vaginal pessary. Pregnancy was confirmed by clinical and ultrasound examinations and plasma hCG assessment. Complete abortion occurred in 72 patients (96%) and the 3 others required a surgical uterine aspiration. Bleeding continued for 4-12 days (mean=8). Uterine pain and side effects occurred during the 3 hours following the use of PG; only minor analgesics were required in 30 patients. The combination of mifepristone and meteneprost is a safe and effective method of terminating and early pregnancy.

MeSH terms

  • 16,16-Dimethylprostaglandin E2 / administration & dosage*
  • 16,16-Dimethylprostaglandin E2 / adverse effects
  • 16,16-Dimethylprostaglandin E2 / analogs & derivatives
  • Abortifacient Agents / administration & dosage*
  • Abortifacient Agents, Nonsteroidal / administration & dosage*
  • Abortifacient Agents, Nonsteroidal / adverse effects
  • Abortion, Induced / methods*
  • Abortion, Legal
  • Administration, Intravaginal
  • Administration, Oral
  • Adolescent
  • Adult
  • Female
  • France
  • Humans
  • Mifepristone / administration & dosage*
  • Mifepristone / adverse effects
  • Pregnancy
  • Pregnancy Trimester, First
  • Prostaglandins E, Synthetic / administration & dosage*

Substances

  • Abortifacient Agents
  • Abortifacient Agents, Nonsteroidal
  • Prostaglandins E, Synthetic
  • meteneprost
  • Mifepristone
  • 16,16-Dimethylprostaglandin E2